Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity.
We investigated the ability of various tumour-necrotizing agents with diverging toxicity to induce tumour necrosis factor (TNF) and cytostatic activity in Propionibacterium-acnes-primed Swiss and tumour-bearing BALB/c mice, and the capacity of anti-TNF antibodies to inhibit induction of tumour necrosis by the agents. Lipid A and especially its combination with muramyl dipeptide induced high TNF levels in Swiss mice, as measured in the serum. Lower levels were induced by detoxified lipid A and the nontoxic dsRNA, polyadenylic.polyuridylic acid, either alone or combined with muramyl dipeptide. The toxic agents also appeared the strongest inducers of mediators with cytostatic activity against cultured endothelial cells and MethA tumour cells. Anti-TNF antibodies partially reduced the cytostatic activity of the sera against MethA cells. Tumour-bearing BALB/c mice produced only low levels of TNF and cytostatic factors in response to all agents. Recombinant mouse TNF hardly reduced the DNA synthesis of MethA cells, unless normal mouse serum was added. Serum from P.-acnes-treated Swiss mice and tumour-bearing BALB/c mice, that were inhibitory on their own, failed to potentiate the action of TNF. Serum from Swiss mice treated with toxic, but not detoxified, lipid A caused extensive tumour necrosis upon injection into MethA-bearing BALB/c mice. This activity was completely abolished by pre-incubation of the serum with anti-TNF. The tumour-necrotizing activity of the agents could be partially reduced by prior injection of these antibodies. Results show that the capacity of the agents to induce TNF and cytostatic activity is not related to their antitumour potential. Although TNF is likely to be a crucial mediator of the tumour-necrotizing action of the toxic as well as the nontoxic agents, it is probably not the sole mediator. Data also indicate that induction of tumour necrosis does not require induction of high and, thus toxic, TNF levels in the serum.
van de Wiel
P A
PA
Research Institute of Toxicology (RITOX), Sector of Immunotoxicology, University of Utrecht, The Netherlands.
van der Pijl
A
A
Bloksma
N
N
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000818:Animals; D001790:Blood Physiological Phenomena; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D005260:Female; D007106:Immune Sera / Q000276:immunology; D008050:Lipid A / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009336:Necrosis; D009374:Neoplasms, Experimental / Q000473:pathology*; D011063:Poly A-U / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000502:physiology*
D007106:Immune Sera; D008050:Lipid A; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D011063:Poly A-U; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D004247:DNA